Brief: Prelude Expects To Report Cash And Cash Equivalents Of $218.3 Million As Of Dec. 31
04/01/2021 22:10
Jan 4 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* PRELUDE THERAPEUTICS INC - EXPECTS TO REPORT CO HAD CASH
AND
CASH EQUIVALENTS OF ABOUT $218.3 MILLION AS OF DECEMBER 31, 2020
Source text: (https://bit.ly/2MyUYws)
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview